This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Paul V. Lehmann, M.D., Ph.D., Professor

CEO, President and Founder

Personal Statement
My entire research career revolved around immune monitoring. Initially I pursued this field entirely in the academic setting. In 1998 I founded a company around immune monitoring, CTL. At CTL we have been continuously refining methods, reagents and instrumentation for improving the ability to reliably detect rare antigen-specific T and B cells in freshly isolated cell material, such as human blood. Not only have we been offering new developments to the scientific community, but we also have been the first ones to apply them in research, continuing to further the field. I personally have been trying to combine my new role as the head of a company that employs close to 150 in the meantime, with directing research in our R&D department, and continued academic productivity in this field.

Education and Training
  • M.D., University of Tübingen, Germany
  • Ph.D., University of Tübingen, Germany
  • 1st Postdoc, Sandoz, Basel, CH, with Z. Nagy and L. Adorini
  • 2nd Postdoc, UCLA, Los Angeles, with Eli Sercarz
  • Assistant, Associate, and Full Professor with Tenure at Case Western, Cleveland
  • CEO of CTL
Peer-reviewed Publications (Google Scholar: h-index 53, 217 publications, 14,703 citations):
See full CV